Trial Profile
A Phase 2/3, Placebo-Controlled, Efficacy and Safety Study of Once-Weekly, Subcutaneous LY2189265 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus on Metformin
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 14 Oct 2021
Price :
$35
*
At a glance
- Drugs Dulaglutide (Primary) ; Metformin; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms AWARD-5
- Sponsors Eli Lilly and Company
- 05 Jun 2018 Results of a post-hoc analysis of AWARD-1, AWARD-5, AWARD-8 and AWARD-9 clinical trials (n=1499) assessing effects of dulaglutide versus placebo on liver and glycaemic/metabolic measurements, published in the Diabetic Medicine
- 15 Sep 2017 Results of pooled post-hoc analysis of AWARD-2,4 and 5 , presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes.
- 15 Sep 2017 Results of a post-hoc analysis assessing effects of dulaglutide on liver enzyme using pooled data from AWARD-1, -5, -8 and -9) presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes